


AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A uracil derivative compound represented by the general formula (I):



wherein X represents a group selected from NHCO, NHCH₂, CO, CONH and CH₂NH; R¹ represents a hydrogen atom or a substituted or unsubstituted alkyl group of 1 to 6 carbon atoms; R² represents the general formula (II) or (III):



wherein m is 0 or 1, n is an integer of 1 to 3, Y is OH or NH₂, and each dotted line indicates a bonding position, provided that when R² represents the general formula (III), X represents NHCO or NHCH₂; R³ and R⁴ independently represent a hydrogen atom or an alkyl group of 1 to 6 carbon atoms; and Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions, a substituted or unsubstituted heteroaryl group or a bicyclic aromatic group, or a pharmaceutically acceptable salt thereof.

2. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R² represents the general formula (II) in the general formula (I).
3. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R² represents the general formula (III) in the general formula (I).
4. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).
5. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).
6. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Ar represents a bicyclic aromatic group in the general formula (I).

7. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein X represents NHCO in the general formula (I).

8. (currently amended): A pharmaceutical composition for the treatment of type IV allergic diseases dermatitis comprising a uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

9. (currently amended): A pharmaceutical composition for the treatment of pruritus induced by substance P comprising a uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

10. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a phenyl group substituted by alkyl groups of 1 to 6 carbon atoms at the o- and m-positions in the general formula (I).

11. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a substituted or unsubstituted heteroaryl group in the general formula (I).

12. (currently amended): A-The uracil derivative compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein Ar represents a bicyclic aromatic group in the general formula (I).

13. (new): A method of using the uracil compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient to treat type IV allergic dermatitis.

14. (new): The pharmaceutical composition according to claim 9, wherein the pruritus induced by substance P is pruritus accompanying atopic dermatitis, pruritus accompanying psoriasis or pruritus in dialysis.

15. (new): A pharmaceutical composition for the treatment of pruritus accompanying atopic dermatitis comprising a uracil compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

16. (new): A method of using the uracil compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient to treat pruritus induced by substance P.

17. (new): The method according to claim 16, wherein the pruritus induced by substance P is pruritus accompanying atopic dermatitis, pruritus accompanying psoriasis or pruritus in dialysis.

18. (new): A method of using the uracil compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient to treat pruritus accompanying atopic dermatitis.